Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Get access
Effective date: July 19, 2024

PMcardio for Organizations End User License Agreement (“EULA”)

Please read this EULA carefully before downloading or using the Powerful Medical mobile application (“Application”), Powerful Medical web application or otherwise accessing or using Powerful Medical subscription services (“Subscription Services”). Please note that (i) if you are located in the United States, you are entering into this EULA with Powerful Medical Inc. and (ii) if you are located outside the United States, you are entering into this EULA with Powerful Medical s.r.o. (each as applicable referred to as “PM”). This EULA governs your use of the Subscription Services which includes the use of the Application made available to you as an authorized user through a hospital or health care facility’s existing agreement governing such Subscription Services (“Customer Agreement”) or, (ii) in the absence of the Customer Agreement as individual healthcare professional. To the extent that this EULA conflicts with the Customer Agreement, the terms of this EULA will apply to you. Your use of the Subscription Services indicates your consent to this EULA. 

  1. License.  Subject to acceptance of this EULA and always in compliance with this EULA, we grant you a non-exclusive, non-transferable license to use the Subscription Services. You represent and warrant that you will only use the Subscription Services utilising either (i) Medical Device Modules (mean technology modules that are registered medical devices that have been cleared by the U.S. Food and Drug Administration, the European Medicines Agency or another applicable authority to be marketed for commercial purposes within the applicable territory) and/or (ii) Research Modules (mean technology modules that are for Investigational Use only) (or in case the Customer Agreement is concluded, Medical Device Modules and Research Modules shall have the meaning attributed to them in the Customer Agreement) only if you are a medical specialist with the requisite clinical expertise to use the Application and the Subscription Services. 
  2. Instructions for Use. The current version of the instructions for use (“Instructions for Use”) is available to you and can be accessed through the Subscription Services. You are allowed to use the Subscription Services only in compliance with the then-current effective version of Instructions for Use, with the sole exception of when certain modules don’t have applicable instructions for their use.
  3. Usage Restrictions.  You agree you will not, nor will you encourage others or assist others to, (a) modify, translate, reverse engineer, decompile, disassemble, or create any derivative works based on the Subscription Services; (b) circumvent any user limits, or other timing, use, or functionality restrictions built into the Subscription Services; (c) remove any proprietary notices, labels, or marks from the Subscription Services; (d) frame or mirror any content forming part of the Subscription Services; (e) access the Subscription Services in order to (i) build a competitive product or service, or (ii) copy any ideas, modules, functions, or graphics of the Subscription Services; (f) use PM’s intellectual property rights (or any related or similar logos or trademarks of PM) for your benefit or (g) use the Subscription Services in a way that is prohibited by the Instructions for Use. You agree you will (z) at all times protect your login credentials and not log in using login credentials of others, nor obtain or collect login credentials of others, (y) not use the Subscription Services in life supporting or sustaining systems, nor in ECG-monitoring and/or alarm devices, (x) always use the Application in compliance with the Instructions for Use. Moreover, specifically in relation to the service account utilizing API access, you agree that you will not (a) frame, distribute, resell, or permit access to the APIs by any third party other than as allowed by the features and functionality of the Subscription Services; (b) interfere with, disrupt, or gain unauthorized access to the service account or API keys; (c) transfer to the service account or API access or otherwise use on the API any code, exploit, or undisclosed feature that is designed to delete, disable, deactivate, interfere with or otherwise harm or provide unauthorized access to the service account or the API. You are responsible for ensuring that your use of the Subscription Services complies with all applicable laws, statutes, regulations and rules. You will not use the Subscription Services except in compliance with this EULA. You agree that you will not use or encourage others to use the Subscription Services in a way that could harm or impair others’ use of the Subscription Services.  
  4. Your Access. PM reserves the right to suspend or terminate your access to the Subscription Services at any time (i) based on the status of your account under the Customer Agreement (e.g. Customer exceeded usage allowance or is in breach of the obligations thereof), (ii) if you violate this EULA in any way (iii) based on PM’s sole discretion, if in its opinion your continuous access to the Subscription Services may have a potential negative effect on PM, or (iv) in case there is no Customer Agreement concluded, based on PM’s sole discretion. You understand that if your account is suspended or terminated, you will no longer have access to the content that is stored within the Subscription Services. 
  5. Investigational Use. If the Application or other part of the Subscription Services is labelled as “Investigational Use Only” or similar on the user interface of the Subscription Services or associated documentation, you acknowledge that the relevant part of the Subscription Services is for investigational use only and should not be used in clinical diagnosis, patient management, or an investigation that is not exempt from 21 CFR part 812 or exempt under the such other applicable laws and regulations, in particular Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. 
  6. Retained Rights. PM retains all right, title, and interest in the Subscription Services, including all copies thereof in any form or medium, whether now known or existing or hereafter developed, and further including all pricing methodologies, models, programs, analytical tools, algorithms, software tools and related methodologies, its copyrights, patents, trade secrets, trademarks or trade names therein. Except to the extent granted herein, you acquire no rights in any of the foregoing. 
  7. Content. The information you enter into the Subscription Services, including files you upload and messages you enter, are referred to as your “Content”.  We don’t control, verify, monitor or endorse the Content that you or others put on the Subscription Services.  You are responsible for (a) all Content you place in the Subscription Services and (b) making sure that you have all the rights you need to the Content.  In addition, by storing, using or transmitting Content you shall not violate any law or this EULA or any rights of a third party.  You agree to provide PM (as well as agents or service providers acting on its behalf to provide the Subscription Services) the right to transmit, process, use and disclose Content and other information which we may obtain as part of your use of the Subscription Services but only: (i) as necessary for us to provide the Subscription Services, (ii) as otherwise permitted by this EULA or the Customer Agreement, (iii) as otherwise required by law, regulation or order, or (iv) to respond to an emergency.  
  8. Feedback.  You are under no obligation to provide any feedback to PM in relation to the Subscription Services, or any other PM offering, and to the extent that you do provide such feedback you do so voluntarily. You agree that any feedback or ideas you provide to us regarding the Application, Subscription Services, or any other offerings of PM or any suggested improvements thereto (together, “Feedback”) will be the exclusive property of PM and upon disclosure of the Feedback, you grant to Powerful Medical an exclusive, sublicensable, perpetual, irrevocable, royalty-free, worldwide license for the full unhindered use of the Feedback. For the avoidance of any doubts, such use shall include, but not be limited to, reproduction, adaptation, translation, modification, transformation, and development of derivative works of, public display, public performance, sublicensing, making available and distribution of the Feedback and any derivative works. To the extent you own any rights in the Feedback, you agree to assign and hereby do assign to us all right, title and interest in and to the Feedback. You agree to perform all acts reasonably requested by us to perfect and enforce such rights. We will reimburse you for direct out of pocket costs incurred in complying with our requests, which are reasonable and approved by PM in advance. 
  9. Copyright. PM respects the intellectual property and will respond to notices of alleged copyright infringement that comply with the law. We reserve the right to delete or disable Content alleged to violate copyright laws or this EULA and reserve the right to disable and/or terminate the account(s) of violators. If you believe there has been a violation of your copyright, please contact legal@powerfulmedical.com or contact us by mail at the following address: (i) if you are located in the United States – 7th floor, 33 West 17th Street, New York, NY, USA or (ii) if you are located outside the United States – CBC I, Karadičova 8/A, 821 08, Bratislava, Slovak Republic . 
  10. Third-Party Services. The Subscription Services may be integrated with third-party applications and services (“Third Party Services”). Your access to and use of any Third Party Services, if any, including any goods, software, services or information made available from those Third Party Services, is governed by the terms and conditions applicable to those Third Party Services. Third Party Services are not owned or operated by PM in any way. YOUR USE OF THIRD PARTY SERVICES IS AT YOUR OWN RISK. PM MAKES NO WARRANTIES, CONDITIONS, INDEMNITIES, REPRESENTATIONS OR TERMS, EXPRESS OR IMPLIED, WHETHER BY STATUTE, COMMON LAW, EQUITY, CUSTOM, USAGE OR OTHERWISE AS TO ANY OTHER MATTERS, INCLUDING BUT NOT LIMITED TO NON-INFRINGEMENT OF THIRD PARTY RIGHTS, TITLE, INTEGRATION, ACCURACY, SECURITY, AVAILABILITY, SATISFACTORY QUALITY, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WITH RESPECT TO THE THIRD PARTY SERVICES. 
  11. Data. You acknowledge that PM is continually improving, adjusting, and testing the Application. You grant PM a non-exclusive, perpetual, irrevocable license to use, reproduce, distribute, display and modify any data, including Content, you enter into the Subscription Services (“Data”) in order to (i) deliver the Subscription Services to you and (ii) modify, adjust, test or improve the Application and the Subscription Services and any algorithms, models or methods used to offer, operate, test, or design the Application or the Subscription Services. PM may use (i) de-identified Personal Data (i.e., data which does not allow an identification of the individual, including a patient) and (ii) aggregated Data with the data of other users where the identification of any particular user cannot be ascertained (“De-Identified Data”) training of its models, benchmarking, product improvement, development of new products, scientific research purposes, for internal operations, including troubleshooting, data analysis, testing, research, for statistical purposes and for improving the quality of Subscription Services, or for any other lawful purpose. 
  12. You acknowledge and accept that PM may notify you about various matters such as new product features, updates or maintenance and may conduct end user satisfaction surveys via the Application.  
  13. Privacy. In order to operate and provide the Subscription Services and the Application, PM may collect certain information about you or about other individuals, such as patients (“Personal Data”). PM uses and protects that information in accordance with the applicable PM Privacy Policy (a current version of which can be found at https://www.powerfulmedical.com/legal/general-privacy). If you use any Third Party Services, PM may pass information about you to the Third Party Services for the purposes of provision of the Subscription Services. Personal Data may in some instances include “Protected Health Information” as defined in the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) or “data concerning health” as defined in Article 4 (15) of the Regulation (EU) 2016/679 of the European Parliament and of the Council on the protection of natural persons with regard to the processing of personal data and on the free movement of such data  (“GDPR”) (together just “PHI”). Processing of PHI is governed either by the HIPAA Business Associate Agreement (“BAA”) or by the GDPR Data Processing Agreement (“DPA”) (as applicable) concluded between the Customer and PM. In case there is no Customer Agreement (i.e. no Business Associate Agreement nor Data Processing Agreement is concluded), such PHI provided by the User to PM for processing will be governed by the User DPA available here, or in case the User is located in the United States or the User and/or PHI is otherwise subject to HIPAA, User BAA available here. The User DPA (applicable in case there is no Customer Agreement and you’re not located in the United States) governs also the processing of other types of Personal Data in relation to which you are deemed a controller and PM is deemed a processor (both as defined under GDPR).
  14. Confidentiality. You acknowledge that in connection with this EULA, and Subscription Services, you have access to PM’s proprietary and confidential information including the Application itself and any associated documentation (“Confidential Information”). You agree that (i) all items of Confidential Information are proprietary to PM and will remain its sole property; (ii) you will only use Confidential Information for the purposes described herein; (iii) you will not reproduce Confidential Information; (iv) you will hold in confidence and protect Confidential Information from dissemination as if it were your own confidential information; and (v) you will return or destroy all Confidential Information that is in your possession upon termination or expiration (as the case may be) of this EULA. Unless terminated otherwise, this EULA is considered to be terminated or expired  (i) at the same time the Customer Agreement (or the relevant order form concluded under the Customer Agreement whereby the Service has been ordered) is terminated or expired, or (ii) in the absence of the Customer Agreement, when your account for the Subscription Services is deleted. Notwithstanding the foregoing, the provisions of this Section will not apply to Confidential Information that (a) is publicly available or in the public domain at the time disclosed or becomes publicly available or enters the public domain through no fault of you; (b) is rightfully communicated to you by persons not bound by confidentiality obligations with respect thereto; (c) is already in your possession free of any confidentiality obligations with respect thereto at the time of disclosure; or (d) is independently developed by you. 
  15. NO WARRANTY. THE APPLICATION, SUBSCRIPTION SERVICES, AND DOCUMENTATION ARE MADE AVAILABLE TO YOU “AS IS” AND WITHOUT WARRANTY OF ANY KIND. PM SPECIFICALLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. PM DOES NOT WARRANT THAT THE SUBSCRIPTION SERVICES, DOCUMENTATION, OR ANY OTHER INFORMATION, MATERIALS AND/OR DATA PROVIDED UNDER THE EULA WILL MEET YOUR REQUIREMENTS OR IS COMPLETE, ACCURATE OR ERROR-FREE. YOU SHALL NOT MAKE ANY REPRESENTATIONS OR WARRANTIES ON BEHALF OF PM. YOU ARE SOLELY RESPONSIBLE FOR BACKING UP ANY OF YOUR DATA. 
  16. Risk Assumption. THE SUBSCRIPTION SERVICES INCLUDING THE APPLICATION ARE INTENDED ONLY AS A SUPPLEMENT TO YOUR KNOWLEDGE AND PROFESSIONAL JUDGMENT AND THAT THE ACCURACY OF THE OUTPUT MAY DEPEND ON THE QUALITY OF THE INPUT DATA. YOU SHALL BE SOLELY RESPONSIBLE FOR ANY PROFESSIONAL DECISIONS YOU MAKE BASED UPON USE OF THE SUBSCRIPTION SERVICES. THE SUBSCRIPTION SERVICES ARE NOT INTENDED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL JUDGEMENT IN PATIENT DIAGNOSIS OR TREATMENT. YOU AGREE THAT YOU SHALL USE THE HIGHEST DEGREE OF CARE WHEN USING THE SUBSCRIPTION SERVICES AND SHALL ANALYZE INFORMATION PROVIDED BY THE SUBSCRIPTION SERVICES IN LIGHT OF ALL OF THE OTHER AVAILABLE INFORMATION BEFORE RELYING ON SUCH INFORMATION OR MAKING DECISIONS REGARDING PATIENT CARE.  YOU ASSUME ALL RISK FOR THE CARE OF YOUR PATIENTS WHEN USING THE SUBSCRIPTION SERVICES AND PM SHALL NOT BE RESPONSIBLE FOR ANY LOSSES, INJURIES, DAMAGES OR OTHER CONSEQUENCES TO YOU OR YOUR PATIENTS RESULTING FROM SUCH USE. PM DOES NOT, NOR DOES IT INTEND TO, ENGAGE IN THE PERFORMANCE OR DELIVERY OF MEDICAL OR HEALTH CARE SERVICES. 
  17. Indemnification. You agree to hold, harmless, indemnify, and, at PM’s option, defend PM from and against any losses, liabilities, costs (including reasonable attorneys’ fees) or damages resulting from your (i) breach of the Instructions for Use or other misuse of the Subscription Services, and (ii) negligence or wilful misconduct. You shall not settle any third-party claim against PM unless such settlement completely releases PM from all liability with respect to such claim or unless PM consents to such settlement, and further provided that PM will have the right, at its option, to defend itself against any such claim or to participate in the defense thereof by a legal counsel of its own choice. 
  18. Limitation of Liability.  To the maximum extent permitted by the applicable law, in no event shall PM be liable to you for any indirect, consequential, special, or incidental damages, or other pecuniary loss, in any way arising out of or related to the Application, Subscription Services, or this EULA, even if PM has been advised of the possibility of such damages.  The cumulative liability of PM to you for all claims arising from or relating to this EULA shall not exceed $500.00. 
  19. Consent to Electronic Communications and Solicitation. You authorize PM to send you (including via email and push notifications) information regarding the Subscription Services, such as: (a) notices about your use of the Subscription Services, including notices of violations of use; (b) updates to the Subscription Services and Application and new features or products; and, only applicable for Users within United States, (c) promotional information and materials regarding PM’s products and services. 
  20. Changes to this EULA. PM reserves the right to modify this EULA. If PM makes material changes to this EULA, we will notify you via the Subscription Services (e.g. via the Application) or on your e-mail. Your continued use of the Subscription Services after PM publishes notice of changes to this EULA indicates your consent to the updated terms. 
  21. Contact Information, Notices. If you have any questions regarding this EULA or you want to send us a notice under this EULA, please send an e-nail to PM at legal@powerfulmedical.com. PM may deliver any notices under this EULA to you either via Subscription Services or on your e-mail.
  22. Dispute Resolution.
    • a) If you are using the Application or Subscription Services in the U.S., this EULA will be governed by the laws of the State of Delaware, without regard to, or application of, rules or principles regarding conflicts of law or the United Nations Convention on the International Sale of Goods. For purposes of all claims brought under this EULA, you irrevocably submit to the exclusive jurisdiction of the state and federal courts located in the State of Delaware. 
    • b) If you are using the Application or Subscription Services outside the U.S., this EULA will be governed by the laws of the Slovak Republic, without regard to, or application of, rules or principles regarding conflicts of law or the United Nations Convention on the International Sale of Goods. Any dispute shall be finally settled under the Rules of Arbitration (Vienna Rules) of the Vienna International Arbitral Centre (VIAC) of the Austrian Federal Economic Chamber by one or three arbitrators appointed in accordance with the said Rules. The place of arbitration shall be Vienna, Austria and language of the proceedings shall be English. This clause shall be governed by and construed exclusively in accordance with the laws of the Slovak Republic.  
    • c) You acknowledge that PM will have the right to seek an injunction if necessary to stop or prevent a breach of your obligations hereunder. In the event that PM prevails in any proceeding or lawsuit brought by either party in connection with this EULA, PM will be, subject to statutory limitations, entitled to receive its costs, expert witness fees and reasonable attorney’s fees, including costs and fees on appeal. 
  23. General. Waiver of a breach of or right hereunder must be in writing and will not constitute a waiver of any other or subsequent breach or right. If any provision of this EULA is held by a court of competent jurisdiction to be contrary to law, that provision shall be changed and interpreted so as to best accomplish the objectives of the original provision to the fullest extent allowed by law, and the remaining provisions herein will remain in full force and effect. You may not assign this EULA without obtaining PM’s prior written consent and any attempted or purported assignment by you shall be null and void. This EULA together with the Customer Agreement (if concluded) constitutes the entire agreement, understanding and representations, expressed or implied, of the parties with respect to the subject matters described herein, and supersedes all prior written and oral communications, agreements, letters of intent, representations, warranties, statements, negotiations, understandings and proposals, with respect to such subject matters.

SPECIFIC PROVISIONS APPLICABLE ONLY TO UNITED STATES USERS 

  1. Legal Compliance. You represent and warrant that (a) you are not located in a country that is subject to a U.S. Government embargo, or that has been designated by the U.S. Government as a “terrorist supporting” country; and (b) you are not listed on any U.S. Government list of prohibited or restricted parties. 

Get updates, insights, and reports on the latest industry trends.

Try PMcardio free — scan your first ECG in under a minute.

Download PMcardio app on the Apple App Store
Get PMcardio app on Google Play Store
Download PMcardio app on the Apple App Store
Get PMcardio app on Google Play Store

Products

Company

Resources

Powerful Medical is redefining the landscape of medical diagnostics with its AI-driven solutions. The company’s PMcardio platform deploys certified AI-ECG Modules that revolutionize the way cardiovascular diseases are detected, offering rapid and accurate diagnostics that pave the way for timely and effective treatment.

 

  • © Powerful Medical 2026
Powerful Medical, Inc. | PMcardio and the PMcardio logo are registered trademarks of Powerful Medical. Additionally, Queen of Hearts is claimed as a trademark of Powerful Medical.

Certain AI ECG Modules are CE-marked medical devices under EU MDR and only certified for marketing in the European Union and the United Kingdom. Powerful Medical technology has not yet been cleared or approved by the US Food and Drug Administration (FDA) for marketing in the USA. Not all modules of the PMcardio platform may be available in your region.

Prior to use, reference the Instructions for Use, for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Get access

All Supported ECG Findings

Rhythms
Sinus bradycardia • Sinus rhythm • Sinus tachycardia • Paced rhythm • Atrial fibrillation
Atrial fibrillation with rapid ventricular response • Atrial fibrillation with slow ventricular response • Atrial flutter • Atrial flutter with rapid ventricular response • Atrial flutter with slow ventricular response • Supraventricular tachycardia • Suspected junctional rhythm • Suspected junctional bradycardia • Suspected accelerated junctional rhythm • Wide QRS rhythm • Idioventricular rhythm • Wide QRS tachycardia

Myocardial Infarctions
  • STEMI
  • STEMI
    Equivalent
Detects occlusive myocardial infarctions (OMIs) even without ST elevation (i.e. posterior STEMI, hyperacute T-waves, etc.). Negative for STEMI mimics (i.e. early repolarization, LVH, etc.)
  • High-Risk NSTEMI
    Represents a type 1 myocardial infarction caused by a transiently recanalized coronary occlusion—classically seen in patterns such as Wellens type A or B due to subtotal LAD obstruction, but possible in any infarct-related territory.
  • Culprit Detection
    AI-predicted likelihood scores for LAD, LCx, and RCA with 3D heart visualization highlighting the predicted culprit artery.

Conduction Abnormalities (Heart Blocks
1st degree AV block • 2nd degree AV block, type Wenckebach • Higher degree AV block • Complete right bundle branch block • Incomplete right bundle branch block • Complete left bundle branch block • Incomplete left bundle branch block • Nonspecific intraventricular conduction delay • Left anterior fascicular block • Left posterior fascicular block • Bifascicular block (RBBB + LAFB) • Bifascicular block (RBBB + LPFB) • Trifascicular block (RBBB + LAFB + AVBLOCK1) • Trifascicular block (RBBB + LPFB + AVBLOCK1)

LVEF
Reduced LVEF (≤40%) • Mildly reduced LVEF (41 – 49%) • No signs of reduced LVEF (≥50%)

Axis
Left cardiac axis deviation • Right cardiac axis deviation • Extreme cardiac axis deviation • Normal axis

Measurements
Heart rate • P wave • PR interval • QRS duration • QT interval • Corrected QT interval (Framingham formula) • RR interval • PP interval • ST elevations

Other Supported Diagnoses
Suspected long QT syndrome • Suspected short QT syndrome • Suspected atrial enlargement • Suspected ventricular hypertrophy • Premature complexes

Dr. Tom De Potter, MD

Cardiologist at the Cardiac Center Aalst

Cardiologist specializing in Pacemaker Device Therapy and Electrophysiology. Leads the electrophysiology unit at the Heart Center in Aalst, holds an executive board position at the European Heart Academy, and serves as EHRA scientific program committee co-chair.

Dr. Martin Penicka, MD, PhD

Cardiologist at the Cardiac Center Aalst

Cardiologist at the Cardiac Center Aalst since 2009, specializing in non-invasive imaging and valvular disease. Fellow of the European Society of Cardiology (FESC) and the European Association of Cardiovascular Imaging (FEACVI).

Dr. Ward Heggermont, MD, PhD

Co-director at the Cardiovascular Center

Co-director at the Cardiovascular Center of Aalst Hospital, specializing in heart failure. Research focus at the intersection of cardiology, virology, and metabolism.

Prof. Dr. Robert Hatala, PhD

Co-founder and Chief Scientist

Head of the Arrhythmia and Pacing department at the National Institute of Cardiovascular Diseases in Slovakia. More than 150 publications and 10,000 citations. Contributor to ESC clinical practice guidelines and executive editor of the European Heart Journal since 2020.

Arieh Levy

Head of PMcardio for Individuals

Arieh leads the PMcardio for Individuals product at Powerful Medical, guiding its development as a clinical tool for emergency physicians, cardiologists, and primary care physicians. He holds a First Class MEng in Biomedical Engineering from Imperial College London, where he specialised in AI for cardiology, building physics-informed neural networks to model atrial electrical properties, giving him a background that bridges the clinical and technical demands of building a certified AI medical device used at the bedside every day.

Dr. Dave Pearson, MD​

Business Advisor

Academic emergency medicine physician, entrepreneur, investor, and researcher with nearly two decades at Atrium Health, one of US largest health systems. Brings expertise at the intersection of clinical care, healthcare innovation, and strategic leadership.

Prof. Stephen W. Smith, MD

Professor of Emergency Medicine

Faculty physician in Emergency Medicine at Hennepin County Medical Center and Professor of Emergency Medicine at the University of Minnesota. Co-inventor of the OMI paradigm and editor of Dr. Smith’s ECG Blog, the most-visited US-based ECG interpretation blog.

Prof. Emanuele Barbato, MD, PhD

President of EAPCI

Interventional cardiologist specializing in coronary artery disease and coronary physiology. Acting president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and contributor to the clinical practice guidelines for STEMI care.

Scott Sharkey, MD

Chief Medical Officer

Chief Medical Officer of the Minneapolis Heart Institute Foundation and practicing cardiologist at Allina Health Minneapolis Heart Institute. Co-founder of the STEMI Midwest consortium and Takotsubo cardiomyopathy research program and a widely published clinical investigator in STEMI care.

Prof. Dr. Leor Perl, MD

Director of Cardiac Catheterization Institute

Director of Complex Cardiac Interventions and Chief Innovation Officer at Rabin Medical Center. Graduate of the Stanford Biodesign Program.

Suzanne J. Baron, MD, MSc

Director of Interventional Cardiology Research

Director of Interventional Cardiology Research at Massachusetts General Hospital. Holds a Master’s degree in health economics from Harvard School of Public Health. Expert in cardiovascular device impact on healthcare costs and patient-reported outcomes.

Prof. Marco Valgimigli, MD

Deputy Chief Cardiocentro Ticino Institute

Head of Cardiology at Cardiocentro Ticino and Principal Investigator of the TITAN-OMI randomized controlled trial. His research has shaped both European and US clinical practice guidelines on coronary stents, antithrombotic therapy, and vascular access.

Timothy D. Henry, MD

Medical Director of The Carl and Edyth Lindner Center

Leading expert in interventional cardiology and STEMI treatment. Co-founder and principal investigator of the Midwest STEMI Consortium, a registry of more than 20,000 consecutive STEMI activations. Presenting author for the TCT 2025 Late-Breaking Clinical Science on Queen of Hearts.

Matus Horvath

Head of People

Matus leads hiring strategy and culture at Powerful Medical. He previously ran the People Team at Slido, the Slovak SaaS startup later acquired by Cisco — an experience that informs how he builds a high-performing, values-driven team through rapid scaling.

Dr. Timea Kisova, MD

Clinical Research Lead

Timea leads Powerful Medical’s global external validation studies, including the multi-country AI ECG TIMI Study. With a background in biomedical sciences and a medical degree from Barts and The London School of Medicine and Dentistry, she brings the clinical discipline required to generate the prospective, real-world evidence behind every PMcardio module.

Dr. Anthony Demolder, MD, PhD

HF Pathway Lead

Research physician with a PhD on arrhythmias in heritable thoracic aortic disease. He has led international studies at the intersection of cardiology and AI — including earlier work on atrial fibrillation at AZ Sint-Jan Brugge — and now drives Powerful Medical’s heart failure pathway and LVsense™ AI model development.

Dr. Pendell Meyers, MD

ACS Pathway Lead

Emergency medicine physician, prolific educator, and Co-Editor of Dr. Smith’s ECG Blog. He is one of the leading voices behind the Occlusion Myocardial Infarction (OMI) paradigm, the clinical framework that reshaped how heart attacks are identified from the ECG — and which sits at the core of the Queen of Hearts™ model.

Adam Dej

Head of PMcardio for Organizations Engineering

Adam leads engineering for PMcardio for Organizations at Powerful Medical, driving platform architecture, backend systems, and infrastructure behind one of the company’s key growth products. He began programming at 13, entered professional IT at 17, and studied computer security at Comenius University’s Faculty of Mathematics, Physics and Informatics. Known for technical depth across distributed systems, infrastructure, and security, he builds scalable and resilient software with a sharp focus on customer impact. He also champions responsible use of AI and LLMs as force multipliers for modern engineering teams.

Gabriela Rovder Sklencarova

Head of Infrastructure

Gabriela designs the scalable, secure, distributed systems that keep PMcardio running around the clock for clinicians worldwide. She joined from Google, where she was a senior software engineer building core libraries that kept Google’s services resilient against billions of requests, and holds a BA and MA in Computer Science from the University of Cambridge.

Arezou Azar

US and Global Regulatory

Arezou leads Powerful Medical’s global regulatory strategy across the FDA, EU MDR, and international frameworks. She has been part of nearly every major breakthrough in AI cardiology and is an expert in US and global regulatory strategy, SaMD/digital health launches, with experience at Eko Health, Verily, AliveCor, Cardiologs, and Apple. She specializes in regulatory strategy in high-paced global organizations.

Adam Rafajdus

Head of AI

Adam grew into the Head of AI role from MLOps Engineer over six years at Powerful Medical, bringing deep expertise in deep learning and production-grade system deployment. He leads the team behind the Queen of Hearts™ AI ECG models and was awarded Best Poster at ISCE 2025 for the company’s ECG digitization pipeline.

Mike Wall

VP of Sales

Mike brings more than twenty years at UnitedHealth Group to the table, where he served health plans, employer groups, and public-sector entities as a consultative healthcare sales executive. He combines market intelligence, clinical insight, and financial acumen — the three ingredients needed to bring AI-powered diagnostics into US health systems at scale.

Amani Farid

Head of Strategic Partnerships

Amani leads partnership strategy with a hands-on approach to integration, unlocking long-term value through collaboration and scale. A University of Chicago Law School-trained attorney and former M&A and capital markets associate at two top international law firms, she brings the rare combination of legal precision and commercial execution refined across nearly a decade at Stryker and as VP of Corporate Development at RapidAI — spanning medtech, digital health, and AI-driven diagnostics.

Michal Martonak

Commercial Lead

A mathematician by training, Michal leads commercial strategy, go-to-market, and strategic partnerships with healthcare providers and clinical institutions worldwide. He previously built Powerful Medical’s data and clinical partnerships function, acquiring the large-scale clinical datasets that underpin the company’s certified AI models.

Dr. Jozef Bartunek, MD, PhD

Co-founder and VP Clinical Strategy

Interventional cardiologist and Co-director of the Cardiovascular Center in Aalst, Belgium — one of the world’s leading heart centers. A Fogarty International NIH Fellow at Harvard Medical School and visiting Professor of Medicine at Catholic University Leuven, he has authored more than 240 peer-reviewed publications in heart failure and structural heart disease, and anchors Powerful Medical’s clinical and research strategy.

Simon Rovder

Co-founder and CTO

Simon began his engineering career at Microsoft and holds a Master’s degree in Informatics from the University of Edinburgh. He built and scaled Powerful Medical’s technology organization from the ground up to a team of 20+ engineers, leading the architecture of a CE-certified Class IIb medical device now deployed in hospitals across Europe.

Viktor Jurasek

Co-founder and CPO

Viktor was modding computer games before his teens and has spent the last decade shipping digital products across advertising, finance, and healthcare. As co-founder and CPO, he has led PMcardio’s product and design since the first prototype, setting the bar for how a clinical-grade tool should feel in a physician’s hands — fast, clear, and trustworthy at the point of care.

Felix Bauer

Co-founder and COO

Felix was part of the Hyperloop team that repeatedly competed and won in Elon Musk’s SpaceX Hyperloop Pod Competition. He holds a degree from the Technical University of Munich and brings a rare combination of engineering rigor, regulatory discipline, and operational excellence to the company, spearheading operations, compliance, regulatory, quality management, and global market access since day one.

Dr. Robert Herman, MD, PhD

Co-founder and Chief Medical Officer

Robert is a physician-scientist who served on the Research, Digital and Innovation Committee of the European Society of Cardiology. He bridges medicine and AI, connecting clinicians, researchers, regulators, and trial leaders to translate algorithms into clinical practice. He founded multiple AI ECG models, leads international clinical trials validating them, is a recipient of the Journal of the American College of Cardiology Spencer King Award, and was named to Forbes 30 Under 30 Europe 2024.

Martin Herman

Co-founder and CEO

Martin started coding at 14 and moved to Silicon Valley at 18, founding several companies including a US-based startup before returning to Europe with his brother Robert to build Powerful Medical. He comes from a family of doctors, which shaped his conviction that AI belongs wherever it can genuinely save lives. Forbes 30 Under 30 (Europe 2024).

Heart Attacks are #1 cause of death world-wide and killing about 12 milions people a year.

Clinical Definition of Problem

Contrary to popular belief, a heart attacks isn’t a blockage inside of the heart. A heart attack is a blockage of the coronary arteries supplying the heart muscle with oxygenated blood.

So let’s assume you get a blood clot here — it blocks the blood flow downstream, meaning the heart muscle doesn’t get oxygenated blood and heart tissue downstream starts to die.

Clinical Solution​

The way to fix it is relatively simple – doctors put in a stent that opens up the artery and renews blood flow. The latest clinical practice guidelines recommend that this “stenting” happens within 90 minutes from symptom onset.

If you don’t, even if you put in the stent in later, the heart tissue downstream has already been permanently damaged, which reduces the heart’s ability to pump blood. This is the leading cause of heart failure and increases 1-year mortality by two-fold.

Time is muscle.

You have just 90 minutes to diagnose the patient, bring them to the hospital and put in the stent, otherwise there is permanent damage. So problem is, that 1 in 2 heart attacks get initially misdiagnosed at the first point of contact.

Discover the future of medical work with us.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.